New treatment in advanced thyroid cancer

Journal of Oncology

Volumn , Issue , 2012, Pages

  Giuffrida, Dario ^a   Prestifilippo, Angela ^a   Scarfia, Alessia ^a   Martino, Daniela ^a   Marchisotta, Stefania ^a  

^a Department of Medical Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CABOZANTINIB; LENVATINIB; MOTESANIB; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SU 1248; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; XL 281;

CANCER THERAPY; CARCINOGENESIS; DIARRHEA; DIFFERENTIATED THYROID CANCER; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAND AND FOOT SKIN REACTION; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; POINT MUTATION; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84869053091     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/391629     Document Type: Review

References (61)

1. Ferlay J., Bray F., Pisani P., Parkin D. M., Cancer incidence, mortality and prevalence worldwide. GLOBOCAN 2002 IARC CancerBase No.5, version 2.0. IARC Press, Lyon, France, 2004
2. Curado M. P., Edwards B., Shin H. R., Cancer Incidence in Five Continents 2007 9 Lyon, France IARC Scientific Publications No. 160
3. Dal Maso L., Bosetti C., La Vecchia C., Franceschi S., Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes and Control 2009 20 1 75 86 2-s2.0-58249105246 10.1007/s10552-008-9219-5
4. Cetani F., Tonacchera M., Pinchera A., Barsacchi R., Basolo F., Miccoli P., Pacini F., Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas. Journal of Endocrinological Investigation 1999 22 4 273 278 2-s2.0-0032935093 (Pubitemid 29224326)
5. Liska J., Altanerova V., Galbavy S., Stvrtina S., Brtko J., Thyroid tumors: histological classification and genetic factors involved in the development of thyroid cancer. Endocrine Regulations 2005 39 3 73 83 2-s2.0-33644866495 (Pubitemid 44788385)
6. Giuffrida D., Gharib H., Current diagnosis and management of medullary thyroid carcinoma. Annals of Oncology 1998 9 7 695 701 2-s2.0-0031826564 10.1023/A:1008242302749 (Pubitemid 28394153)
7. Giuffrida D., Gharib H., Anaplastic thyroid carcinoma: current diagnosis and treatment. Annals of Oncology 2000 11 9 1083 1089 2-s2.0-0033783980 10.1023/A:1008322002520
8. Matsuo K., Tang S. H., Zeki K., Aberrant DNA methylation in human thyroid tumors. The Journal of Clinical Endocrinology & Metabolism 1993 77 991 995 (Pubitemid 23301475)
9. Matsuo K., Tang S. H., Fagin J. A., Allelotype of human thyroid tumors: loss of chromosome 11q13 sequences in follicular neoplasms. Molecular Endocrinology 1991 5 12 1873 1879 2-s2.0-0026408604
10. Giehl K., Oncogenic Ras in tumour progression and metastasis. Biological Chemistry 2005 386 3 193 205 2-s2.0-16844376315 10.1515/BC.2005.025 (Pubitemid 40485425)
11. Gire V., Wynford-Thomas D., RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene 2000 19 6 737 744 2-s2.0-0034628416 (Pubitemid 30107704)
12. Lemoine N. R., Mayall E. S., Wyllie F. S., Williams E. D., Goyns M., Stringer B., Wynford-Thomas D., High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989 4 2 159 164 2-s2.0-0024560104 (Pubitemid 19096939)
13. Suarez H. G., Du Villard J. A., Severino M., Caillou B., Schlumberger M., Tubiana M., Parmentier C., Monier R., Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990 5 4 565 570 2-s2.0-0025265096
14. Shi Y. F., Zou M. J., Schmidt H., Juhasz F., Stensky V., Robb D., Farid N. R., High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Research 1991 51 10 2690 2693 2-s2.0-0025859867
15. Santoro M., Grieco M., Melillo R. M., Fusco A., Vecchio G., Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. European Journal of Endocrinology 1995 133 5 513 522 2-s2.0-0028810126
16. Grieco M., Santoro M., Berlingieri M. T., Melillo R. M., Donghi R., Bongarzone I., Pierotti M. A., Della Porta G., Fusco A., Vecchio G., PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990 60 4 557 563 2-s2.0-0025022463 10.1016/0092-8674(90)90659-3 (Pubitemid 20083812)
17. Castellone M. D., Santoro M., Dysregulated RET signaling in thyroid cancer. Endocrinology and Metabolism Clinics of North America 2008 37 2 363 374 2-s2.0-43849107087 10.1016/j.ecl.2008.02.006 (Pubitemid 351698089)
18. Fusco A., Grieco M., Santoro M., A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987 328 6126 170 172 2-s2.0-0023198108 (Pubitemid 17108219)
19. Wirtschafter A., Schmidt R., Rosen D., Kundu N., Santoro M., Fusco A., Multhaupt H., Atkins J. P., Rosen M. R., Keane W. M., Rothstein J. L., Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 1997 107 1 95 100 2-s2.0-0031031158 10.1097/00005537-199701000-00019 (Pubitemid 27045201)
20. Grieco M., Cerrato A., Santoro M., Fusco A., Melillo R. M., Vecchio G., Cloning and characterization of H4(D10S170), a gene involved in RET rearrangements in vivo. Oncogene 1994 9 9 2531 2535 2-s2.0-0028122473
21. Pierotti M. A., Santoro M., Jenkins R. B., Sozzi G., Bongarzone I., Grieco M., Monzini N., Miozzo M., Herrmann M. A., Fusco A., Hay I. D., Porta G. D., Vecchio G., Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proceedings of the National Academy of Sciences of the United States of America 1992 89 5 1616 1620 2-s2.0-0026565264
22. Santoro M., Dathan N. A., Berlingieri M. T., Bongarzone I., Paulin C., Grieco M., Pierotti M. A., Vecchio G., Fusco A., Molecular characterization of RET/PTC3; A novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994 9 2 509 516 2-s2.0-0027955122 (Pubitemid 24041530)
23. Nikiforov Y. E., Rowland J. M., Bove K. E., Monforte-Munoz H., Fagin J. A., Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research 1997 57 9 1690 1694 2-s2.0-0030941779 (Pubitemid 27199660)
24. Caudill C. M., Zhu Z., Ciampi R., Stringer J. R., Nikiforov Y. E., Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to γ -radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. Journal of Clinical Endocrinology and Metabolism 2005 90 4 2364 2369 2-s2.0-17844394699 10.1210/jc.2004-1811 (Pubitemid 40586286)
25. Elisei R., Romei C., Vorontsova T., Cosci B., Veremeychik V., Kuchinskaya E., Basolo F., Demidchik E. P., Miccoli P., Pinchera A., Pacini F., RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. Journal of Clinical Endocrinology and Metabolism 2001 86 7 3211 3216 2-s2.0-17844407157 10.1210/jc.86.7.3211 (Pubitemid 32673490)
26. Bongarzone I., Pierotti M. A., Monzini N., Mondellini P., Manenti G., Donghi R., Pilotti S., Grieco M., Santoro M., Fusco A., Vecchio G., Della Porta G., High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989 4 12 1457 1462 2-s2.0-0024306507 (Pubitemid 20008924)
27. Bounacer A., Wicker R., Caillou B., Cailleux A. F., Sarasin A., Schlumberger M., Suárez H. G., High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997 15 11 1263 1273 2-s2.0-0030929178 (Pubitemid 27429741)
28. Santoro M., Carlomagno F., Hay I. D., Herrmann M. A., Grieco M., Melillo R., Pierotti M. A., Bongarzone I., Della Porta G., Berger N., Peix J. L., Paulin C., Fabien N., Vecchio G., Jenkins R. B., Fusco A., Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. Journal of Clinical Investigation 1992 89 5 1517 1522 2-s2.0-0026763062
29. Viglietto G., Chiappetta G., Martinez-Tello F. J., Fukunaga F. H., Tallini G., Rigopoulou D., Visconti R., Mastro A., Santoro M., Fusco A., RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995 11 6 1207 1210 2-s2.0-0028825189
30. Zou M., Shi Y., Farid N. R., Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer 1994 73 176 1780
31. Tallini G., Santoro M., Helie M., Carlomagno F., Salvatore G., Chiappetta G., Carcangiu M. L., Fusco A., RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clinical Cancer Research 1998 4 2 287 294 2-s2.0-0031933680 (Pubitemid 28122740)
32. Niccoli-Sire P., Murat A., Rohmer V., Franc S., Chabrier G., Baldet L., Maes B., Savagner F., Giraud S., Bezieau S., Kottler M. L., Morange S., Conte-Devolx B., Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship in a large series of patients. Journal of Clinical Endocrinology and Metabolism 2001 86 8 3746 3753 2-s2.0-17944370976 10.1210/jc.86.8.3746 (Pubitemid 32755971)
33. De Maria R., Elisei R., Giuffrida D., Machens A.,. Thyroid cancer guidelines, 2011
34. Xing M., BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews 2007 28 7 742 762 2-s2.0-37349131738 10.1210/er.2007-0007 (Pubitemid 350294294)
35. Tezelman S., Clark O. H., Current management of thyroid cancer. Advances in Surgery 1995 28 191 221 2-s2.0-0029183262
36. Cooper D. S., Doherty G. M., Haugen B. R., Kloos R. T., Lee S. L., Mandel S. J., Mazzaferri E. L., McIver B., Sherman S. I., Tuttle R. M., Smith B. R., Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006 16 2 109 142 2-s2.0-33645465719 10.1089/thy.2006.16.109
37. Jimenez C., Hu M. I., Gagel R. F., Management of medullary thyroid carcinoma. Endocrinology and Metabolism Clinics of North America 2008 37 481 496 (Pubitemid 351698091)
38. Cohen E. E. W., Needles B. M., Cullen K. J., Phase 2 study of sunitinib in refractory thyroid cancer. Journal of Clinical Oncology 2008 26, abstract 6025
39. Goulart B., Carr L., Martins R. G., Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC). Journal of Clinical Oncology 2008 26, abstract 6062
40. Carr L. L., Mankoff D. A., Goulart B. H., Eaton K. D., Capell P. T., Kell E. M., Bauman J. E., Martins R. G., Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clinical Cancer Research 2010 16 21 5260 5268 2-s2.0-78049462514 10.1158/1078-0432.CCR-10-0994
41. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. Journal of Clinical Endocrinology and Metabolism 2006 91 2 498 505 2-s2.0-32544437659 10.1210/jc.2005-1534 (Pubitemid 43236915)
42. Gupta-Abramson V., Troxel A. B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., Mandel S. J., Flaherty K. T., Loevner L. A., O'Dwyer P. J., Brose M. S., Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 2008 26 29 4714 4719 2-s2.0-50649095250 10.1200/JCO.2008.16. 3279
43. Kloos R. T., Ringel M. D., Knopp M. V., Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 2009 27 10 1675 1684
44. Ahmed M., Barbachano Y., Riddell A., Hickey J., Newbold K. L., Viros A., Harrington K. J., Marais R., Nutting C. M., Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. European Journal of Endocrinology 2011 165 2 315 322 2-s2.0-79960179069 10.1530/EJE-11-0129
45. Hoftijzer H., Heemstra K. A., Morreau H., Stokkel M. P., Corssmit E. P., Gelderblom H., Weijers K., Pereira A. M., Huijberts M., Kapiteijn E., Romijn J. A., Smit J. W., Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European Journal of Endocrinology 2009 161 6 923 931 2-s2.0-72949106263 10.1530/EJE-09-0702
46. Lam E. T., Ringel M. D., Kloos R. T., Prior T. W., Knopp M. V., Liang J., Sammet S., Hall N. C., Wakely P. E., Vasko V. V., Saji M., Snyder P. J., Wei L., Arbogast D., Collamore M., Wright J. J., Moley J. F., Villalona-Calero M. A., Shah M. H., Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology 2010 28 14 2323 2330 2-s2.0-77952468875 10.1200/JCO.2009.25.0068
47. Cabanillas M. E., Kurzrock R., Sherman S. I., Phase I trial of combination sorafenib and tipifarnib: the experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Journal of Clinical Oncology 2010 28 supplement, abstract 5586
48. Wells S. A. Jr., Gosnell J. E., Gagel R. F., Moley J., Pfister D., Sosa J. A., Skinner M., Krebs A., Vasselli J., Schlumberger M., Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Oncology 2010 28 5 767 772 2-s2.0-77649214078 10.1200/JCO.2009.23.6604
49. Robinson B. G., Paz-Ares L., Krebs A., Vasselli J., Haddad R., Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2010 95 6 2664 2671 2-s2.0-77954478933 10.1210/jc.2009-2461
50. Wells S. A. Jr., Robinson B. G., Gagel R. F., Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2012 30 134 141
51. Schlumberger M. J., Elisei R., Bastholt L., Wirth L. J., Martins R. G., Locati L. D., Jarzab B., Pacini F., Daumerie C., Droz J. P., Eschenberg M. J., Sun Y. N., Juan T., Stepan D. E., Sherman S. I., Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. Journal of Clinical Oncology 2009 27 23 3794 3801 2-s2.0-68949108390 10.1200/JCO.2008.18.7815
52. Santarpia L., Ye L., Gagel R. F., Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. Journal of Internal Medicine 2009 266 1 99 113 2-s2.0-66849128386 10.1111/j.1365-2796.2009. 02112.x
53. Rugo H. S., Herbst R. S., Liu G., Park J. W., Kies M. S., Steinfeldt H. M., Pithavala Y. K., Reich S. D., Freddo J. L., Wilding G., Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Journal of Clinical Oncology 2005 23 24 5474 5483 2-s2.0-24944453855 10.1200/JCO.2005.04.192
54. Cohen E. E. W., Rosen L. S., Vokes E. E., Kies M. S., Forastiere A. A., Worden F. P., Kane M. A., Sherman E., Kim S., Bycott P., Tortorici M., Shalinsky D. R., Liau K. F., Cohen R. B., Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of Clinical Oncology 2008 26 29 4708 4713 2-s2.0-50649095801 10.1200/JCO.2007.15.9566
55. Kurzrock R., Sherman S. I., Ball D. W., Forastiere A. A., Cohen R. B., Mehra R., Pfister D. G., Cohen E. E. W., Janisch L., Nauling F., Hong D. S., Ng C. S., Ye L., Gagel R. F., Frye J., Müller T., Ratain M. J., Salgia R., Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Journal of Clinical Oncology 2011 29 19 2660 2666 2-s2.0-79959936054 10.1200/JCO.2010.32.4145
56. Bible K. C., Smallridge R. C., Maples W. J., Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. Proceedings of the American Society of Clinical Oncology 2009 27, abstract 3521
57. Matsui J., Funahashi Y., Uenaka T., Watanabe T., Tsuruoka A., Asada M., Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clinical Cancer Research 2008 14 17 5459 5465 2-s2.0-53049085556 10.1158/1078-0432.CCR-07-5270
58. Glen H., Boss D., Evans T. R., A phase I dose finding study of E7080 in patients with advanced malignancies. Journal of Clinical Oncology 2007 25 18, abstract 14073 Supplement, ASCO Annual Meeting Proceedings
59. Sherman S. I., Jarzab B., Cabanillas M. E., Phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiate thyroid cancer (DTC). Journal of Clinical Oncology 2011 abstract 5503 ASCO Annual Meeting Proceedings
60. Conticello C., Adamo L., Giuffrida R., Vicari L., Zeuner A., Eramo A., Anastasi G., Memeo L., Giuffrida D., Iannolo G., Gulisano M., De Maria R., Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. Journal of Clinical Endocrinology and Metabolism 2007 92 5 1938 1942 2-s2.0-34249851194 10.1210/jc.2006-2157 (Pubitemid 46997213)
61. Grande E., Diez J. J., Zafon C., Thyroid cancer: molecular aspects and new therapeutic strategies. Journal of Thyroid Research 2012 1, article 10